Moderna cancer therapy with Merck’s Keytruda cut mortality by 49% in mid-stage trial

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...